Evidence map›Paper›PMID 30012210›Full record

ArticleJournal for immunotherapy of cancer2018

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).

Julie R Brahmer, Ramaswamy Govindan, Robert A Anders, Scott J Antonia, Sarah Sagorsky, Marianne J Davies, Steven M Dubinett, Andrea Ferris, Leena Gandhi, Edward B Garon and 11 more

Open access · goldAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 157 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
157citing papers in PubMed, 8 pooled it
12.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

157 citing papers in PubMed, 8 syntheses or guidelines pooled it, 244 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

97 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 18 institutions in 1 country.

Julie R BrahmerBloomberg Kimmel Immunotherapy Institute, Johns Hopkins Kimmel Cancer Center, Baltimore, MD, 21231, USA.
Ramaswamy GovindanDivision of Oncology, Washington University, St Louis, MO, 63110, USA.
Robert A AndersJohns Hopkins School of Medicine, Baltimore, MD, 21231, USA.
Scott J AntoniaH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Sarah SagorskyJohns Hopkins Kimmel Cancer Center, Baltimore, MD, 21231, USA.
Marianne J DaviesYale Comprehensive Cancer Center, Yale University School of Nursing, New Haven, CT, 06520, USA.
Steven M DubinettUniversity of California Los Angeles Lung Cancer Research Program, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
Andrea FerrisLUNGevity, Chicago, IL, 60604, USA.
Leena GandhiDepartment of Medicine, New York University, Perlmutter Cancer Center, NYU School of Medicine, New York, NY, 10016, USA.
Edward B GaronDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, 90404, USA.
Matthew D HellmannDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Fred R HirschUniversity of Colorado Denver School of Medicine, Denver, CO, 80011, USA.
Shakuntala MalikNational Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Rockville, USA.
Joel W NealDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Vassiliki A PapadimitrakopoulouUniversity of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
David L RimmDepartment of Pathology, Yale University School of Medicine, New Haven, CT, 06520, USA.
Lawrence H SchwartzDepartment of Radiology, Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York City, NY, 10032, USA.
Boris SepesiThoracic Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Beow Yong YeapDepartment of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Naiyer A RizviColumbia University Medical Center, New York, NY, 10028, USA.
Roy S HerbstYale Comprehensive Cancer Center, Yale School of Medicine, 333 Cedar Street, WWW221, New Haven, CT, 06520-8028, USA. roy.herbst@yale.edu.
The University of Texas MD Anderson Cancer Center · USUniversity of California, Los Angeles · USYale University · USBloomberg (United States) · USColumbia University · USColumbia University Irving Medical Center · USJohns Hopkins University · USLUNGevity Foundation · USMassachusetts General Hospital · USMemorial Sloan Kettering Cancer Center · USMoffitt Cancer Center · USNational Cancer Institute · USNYU Langone’s Laura and Isaac Perlmutter Cancer CenterSidney Kimmel Cancer Center · USStanford University · USUniversity of Colorado Denver · USWashington University in St. Louis · USYale Cancer Center · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
6 · The paper itself

Abstract

Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy - characterized by some benefit but only rare durable responses - was the only treatment option for patients with NSCLC whose tumors lacked targetable mutations. By contrast, immune checkpoint inhibitors have demonstrated distinctly durable responses and represent the advent of a new treatment approach for patients with NSCLC. Three immune checkpoint inhibitors, pembrolizumab, nivolumab and atezolizumab, are now approved for use in first- and/or second-line settings for selected patients with advanced NSCLC, with promising benefit also seen in patients with stage III NSCLC. Additionally, durvalumab following chemoradiation has been approved for use in patients with locally advanced disease. Due to the distinct features of cancer immunotherapy, and rapid progress in the field, clinical guidance is needed on the use of these agents, including appropriate patient selection, sequencing of therapies, response monitoring, adverse event management, and biomarker testing. The Society for Immunotherapy of Cancer (SITC) convened an expert Task Force charged with developing consensus recommendations on these key issues. Following a systematic process as outlined by the National Academy of Medicine, a literature search and panel voting were used to rate the strength of evidence for each recommendation. This consensus statement provides evidence-based recommendations to help clinicians integrate immune checkpoint inhibitors into the treatment plan for patients with NSCLC. This guidance will be updated following relevant advances in the field.

Indexed as

Antineoplastic Agents, ImmunologicalCarcinoma, Non-Small-Cell LungConsensusHumansImmunotherapyLung NeoplasmsSocieties, MedicalAntineoplastic Agents, ImmunologicalCancer immunotherapyConsensus statementGuidelineLung cancerNon-small cell lung cancer

Identifiers

PMID30012210
PMCPMC6048854
OpenAlexW2884259031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.